Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.

ABSTRACT:

Purpose

To identify baseline factors associated with change in visual acuity or development of vision-impairing central-involved diabetic macular edema (DME) over 2 years when treating proliferative diabetic retinopathy (PDR) with ranibizumab or panretinal photocoagulation (PRP).

Design

Post hoc analyses of randomized, multicenter clinical trial data.

Participants

Eyes completing the 2-year visit (n = 328) or without vision-impairing central-involved DME at baseline (n = 302) in Diabetic Retinopathy Clinical Research Network Protocol S.

Methods

Intravitreous ranibizumab (0.5 mg/0.05 ml) or PRP.

Main outcome measures

Change in visual acuity (area under the curve) and development of vision-impairing (20/32 or worse) central-involved DME over 2 years.

Re

SUBMITTER: Bressler SB 

PROVIDER: S-EPMC6566865 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature